Via Insights Bio: "Challenges and benefits in harnessing platform processes for viral vector manufacture"

April 23, 2024
Vector Processing and Material through CGT Insights

Challenges and benefits in harnessing platform processes for viral vector manufacture

DHC Senior Principal and Head of Gene Tx CMC Scott Cross, M.S., Senior Consultant Christina Fuentes, Ph.D., and Principal Jacob Staudhammer were interviewed through Insights Bio's Cell & Gene Therapy Insights in the following publication which came out on April 23, 2024.

As the demand for AAV and lentiviral vector-driven gene therapies continues to grow, the manufacturing space must overcome manufacturing challenges including issues of cost, scalability, and consistency. David McCall, Senior Editor, BioInsights, spoke with Dark Horse Consulting Group’s Scott Cross, Christina Fuentes, and Jacob Staudhammer (pictured left to right) about the current utility and future potential of platform technologies and processes for viral vector manufacturing.

Continue reading here.

Cell & Gene Therapy Insights 2024; 10(3), 339–344

DOI: 10.18609/cgti.2024.049

Related Posts

Join the Quarter Horse Newsletter

We’ll send you a quarterly newsletter all things DHC!
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.